The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|August 18, 2015
GSK Factory in Tianjin Affected by Explosion
Author(s)Pharmaceutical Technology Editors
GSK reports no employee injuries at the facility and is assessing damage.
Advertisement
A GlaxoSmithKline factory located in Tianjin, China-near the site of an Aug. 12, 2015 warehouse explosion-was affected but no employees were injured, according to a company statement. The company has two facilities in the area.
The statement reports that the company has taken “urgent measures to ensure the safety of employees and their families, and to assess plant damage.”
GlaxoSmithKline (Tianjin) Co., Ltd. and American Tianjin Smith Kline Pharmaceutical Co., Ltd. will jointly donate one million yuan ($156,00) to the China Red Cross and is ready to provide any drugs for the recovery effort, the statement reports.
The explosion in an industrial area of the port city has claimed more than 100 lives, with more than 100 people listed as missing.
Source:
Advertisement
Related to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Advertisement
Advertisement